Drug Trial Radar · NCT07371624
A Study of B2065 in Patients With Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Dec 31, 2025
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Tasly Pharmaceutical Group Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection. It will also assess whether B2065 works to treat acute ischemic stroke. The main questions it aims to answer are: At what dose range is the drug safe for participants? Which dose shows preliminary efficacy? Researchers will compare B2065 to a placebo (a look-alike substance that contains no drug) to see if B2065 works to treat acute ischemic stroke. Participants will: Receive a single dose of B2065 during hospitalization Visit the hospital as scheduled for safety and efficacy assessments
Conditions
- Acute Ischemic Stroke
Interventions
B2065Drug
Administered by intravenous infusion.
PlaceboDrug
Administered by intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicities (DLTs) [Safety]Time frame: Within 28 days after dosing.
- Incidence of Infusion-Related Reactions [Safety]Time frame: Within 7 days, 14 days, and 28 days.
- All-Cause Mortality Rate [Safety]Time frame: Within 14 days,12 months, and 24 months.
- Incidence of abnormal imaging findings indicative of tumorigenicity [Safety]Time frame: Month 6 and month 24.
- Change from baseline in serum tumor marker levels [Safety]Time frame: Change from baseline at Month 6 and Month 24.
- Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) [Safety]Time frame: Day1 to month 24 post-dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.